Alternative Data for ARS Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 297 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,436 | Sign up | Sign up | Sign up |
| X Followers | 581 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 82 | Sign up | Sign up | Sign up |
| Linkedin Employees | 175 | Sign up | Sign up | Sign up |
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
| Price | $10.57 |
| Target Price | Sign up |
| Volume | 1,330,000 |
| Market Cap | $1.03B |
| Year Range | $6.73 - $18.35 |
| Dividend Yield | 0% |
| PE Ratio | 152.44 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy RatingJanuary 9 - Yahoo Entertainment |
 |
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond JamesJanuary 9 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 33M | 8.2M | 24M | -51M | -49M | -0.520 |
| Q2 '25 | 16M | 5M | 11M | -45M | -45M | -0.460 |
| Q1 '25 | 8M | 4M | 3.9M | -34M | -37M | -0.350 |
| Q4 '24 | 87M | 3.9M | 83M | 50M | 47M | 0.510 |
| Q3 '24 | 2.1M | 110,000 | 2M | -19M | -22M | -0.200 |
Insider Transactions View All
| Dorsey Brian filed to sell 10,789 shares at $8.7. November 14 '25 |
| Chakma Justin filed to sell 136,380 shares at $8.9. November 14 '25 |
| Scott Kathleen D. filed to sell 10,042 shares at $15. August 22 '25 |
| Lowenthal Richard E filed to sell 1,196,494 shares at $14.5. August 22 '25 |
Similar companies
Read more about ARS Pharmaceuticals (SPRY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - ARS Pharmaceuticals
The Market Cap of ARS Pharmaceuticals is $1.03B.
As of today, ARS Pharmaceuticals' PE (Price to Earnings) ratio is 152.44.
Currently, the price of one share of ARS Pharmaceuticals stock is $10.57.
The SPRY stock price chart above provides a comprehensive visual representation of ARS Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ARS Pharmaceuticals shares. Our platform offers an up-to-date SPRY stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, ARS Pharmaceuticals (SPRY) does not offer dividends to its shareholders. Investors interested in ARS Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of ARS Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
